miR-20b Inhibits T Cell Proliferation and Activation via NFAT Signaling Pathway in Thymoma-Associated Myasthenia Gravis

Figure 1

Expression levels of miR-20b are downregulated in thymoma tissue and serum samples from patients with thymoma-associated myasthenia gravis, as well as in activated T cell. (a) Expression levels of miR-20b as determined by qRT-PCR in thymoma tissue specimens from 30 thymoma-associated myasthenia gravis patients compared to those in adjacent nontumor tissue samples and (b) in serum samples from 30 patients with thymoma-associated myasthenia gravis, 18 patients without, and 15 normal samples from healthy participants. (c) Expression levels of miR-20b were determined by qRT-PCR at different time points (0, 1, 2, and 3, d) in activated Jurkat cells. (d) Human CD4⁺ cells were isolated from human peripheral blood, and miR-20b expression was determined by qRT-PCR at different time points (0, 1, 2, and 3, d) in activated CD4⁺ cells. .

(a)

(b)

(c)

(d)